Most compounding pharmacies assign BUDs based on three factors: the sterility of their compounding environment, the results of any stability testing they have conducted, and the default guidelines from USP 797
The FDA is aware of the issues arising from labels mentioning GLP-1 but has no future or intended action on the matter, said Kyle Diamantas, then deputy foods commissioner and now acting FDA commissioner, in a March 24 interview with Bloomberg Law
After two weeks of treatment with liraglutide, the patient noted the appearance of new psoriatic lesions that continued to progress over two months
Lilly has the following drugs in launch and late phase programs: Tirzepatide Orforglipron Eloralintide Retatrutide Brenipatide These products, along with six additional clinical stage programs and 34 discovery programs, have the potential to help 1 billion people across the following indications: Obesity Diabetes Obstructive sleep apnea Pain Cardiovascular Renal Hepatic During the Q&A portion of the presentation, Ricks responded to a question about his key takeaways from 2025 by saying, We think about both market growth and Lily's position within the US market
Petermann-Rocha F, Ferguson LD, Gray SR, Rodrguez-Gmez I, Sattar N, Siebert S, Ho FK, Pell JP, Celis-Morales C
